Effect of lovastatin pre-treatment on viability at clinically attainable concentrations

(A) Viability as assessed by Trypan blue staining: HL60 cells were treated with 1, 3 or 12 mM lovastatin on Day 0. Mevalonate (200 mM) was added to the cells on day 1, 2, 3, 4 or 5. The effects on viability determined on day 6 as measured by cell counts and Trypan blue uptake. ¼ 2; one example is shown. (B) Ability to recover from lovastatin after 72 h of exposure. HL60 or U937 cells were exposed to lovastatin for 72 h and then rescued with mevalonate (200 mM). They were allowed to proliferate for an additional 6 days. The IC was determined after a total of 3 days of lovastatin exposure and 6 days of mevalonate-rescued growth, i.e. on day 9. Two separate assays were performed and the results for each are as shown (¼ 2 for each cell line, with the individual samples indicated by “A” or “B”). For comparison purposes, the IC50 values as determined previously are plotted (same data as , day 6).Copyright information:Taken from "Statins induce lethal effects in acute myeloblastic lymphoma cells within 72 hours"Leukemia & Lymphoma 2008;49(2):322-330.Published online Jan 2008PMCID:PMC2430172.